CABA

CABA

USD

Cabaletta Bio Inc. Common Stock

$2.700-0.160 (-5.594%)

リアルタイム価格

Healthcare
バイオテクノロジー
米国

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$2.860

高値

$2.970

安値

$2.630

出来高

3.67M

企業ファンダメンタルズ

時価総額

247.0M

業種

バイオテクノロジー

United States

取引統計

平均出来高

3.63M

取引所

NMS

通貨

USD

52週レンジ

安値 $0.986現在値 $2.700高値 $5.46

関連ニュース

GlobeNewswire

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis

もっと見る
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Analyst Upgrades

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

もっと見る
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
Analyst Upgrades

Cantor Fitzgerald Maintains Overweight on Cabaletta Bio, Raises Price Target to $30

Cantor Fitzgerald analyst Josh Schimmer maintains Cabaletta Bio with a Overweight and raises the price target from $15 to $30.

もっと見る
Cantor Fitzgerald Maintains Overweight on Cabaletta Bio, Raises Price Target to $30
GlobeNewswire

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no

もっと見る
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025